2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Tuesday, October 23, 2018

9:00AM-11:00AM: Abstract Number: 2592

Real-World Use of Secukinumab in Psoriatic Arthritis: First Year Data from the Czech National Registry

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2463

Reducing Time to Treatment in Patients with Early and Uncontrolled RA: Implementation of a Collaborative and Systems-Based Approach to Improve Access to Care

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III: Complications of Therapy, Outcomes, and Measures

9:00AM-11:00AM: Abstract Number: 2396

Reduction in the Utilization of Prednisone and/or Methotrexate Following the Initiation of Etanercept in Pediatric Patients

Pediatric Rheumatology – Clinical Poster III: Juvenile Idiopathic Arthritis and Uveitis

9:00AM-11:00AM: Abstract Number: 2274

Refractory and Severe Uveitic Cystoid Macular Edema Improves with Tocilizumab in Different Immune Mediated Diseases

Miscellaneous Rheumatic and Inflammatory Diseases Poster III: Sarcoid, Inflammatory Eye Disease, and Autoinflammatory Disease

9:00AM-11:00AM: Abstract Number: 2188

Regional Analysis of Impact of Participation in a Patient Support Program on Clinical Outcomes Among Patients with Rheumatoid Arthritis Receiving Adalimumab (Humira)

Health Services Research Poster III – ACR/ARHP

9:00AM-11:00AM: Abstract Number: 2622

Regional and Temporal Variation in the Baseline Profile of Ankylosing Spondylitis Patients Initiating Adalimumab Following Failure of Non-Biologic Treatment in Canadian Routine Care

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 1984

Regulation of Multiple Differentiation Potential in Mesenchymal Stem Cells Via an Intercellular Ca2+ Signaling Pathway

Osteoarthritis and Joint Biology – Basic Science Poster II

9:00AM-11:00AM: Abstract Number: 2648

Relationship between Damage and Mortality in Juvenile-Onset Systemic Lupus Erythematosus: Cluster Analyses in a Large Cohort from the Spanish Society of Rheumatology Lupus Registry

Systemic Lupus Erythematosus – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2170

Relationship between Short- and Long-Term Periods of Self-Reported Physical Activity Patterns in Individuals with SLE

Epidemiology and Public Health Poster III – ARHP

9:00AM-11:00AM: Abstract Number: 2494

Relationship between Specific Joint Involvement and Work/Activity Impairment in Rheumatoid Arthritis Patients: Implications for Clinical Practice

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III: Complications of Therapy, Outcomes, and Measures

9:00AM-11:00AM: Abstract Number: 2698

Renal Involvement in Mixed Connective Tissue Disease: A Single Center Experience

Systemic Sclerosis and Related Disorders – Clinical Poster III

9:00AM-11:00AM: Abstract Number: 2700

Rescuing Standard Analyses of Immunosuppresive Rescue Therapy in Randomized Controlled Trials: Alternative Approaches in a Scleroderma Clinical Trial

Systemic Sclerosis and Related Disorders – Clinical Poster III

9:00AM-11:00AM: Abstract Number: 1972

Resolving the Synovial Fluid Proteome and Peptidome for Disease-Specific Mediators of Inflammatory Arthritis

Genetics, Genomics and Proteomics Poster

9:00AM-11:00AM: Abstract Number: 2085

Response Gene to Complement-32 Promotes Kidney Damage in Immune Complex –Mediated Glomerulonephritis

Systemic Lupus Erythematosus – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 2303

Response Rates for Hip, Femoral Neck, and Lumbar Spine Bone Mineral Density in Patients Treated with Abaloparatide Followed By Alendronate

Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at abstracts@rheumatology.org.